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Letter to the EditorinZika  virus  and  its implication  
Zika virus (ZIKV), an emerging ﬂavivirus, was initially isolated
in 1947 from a Rhesus monkey in Uganda. The ﬁrst evidence
of human transmission of ZIKV was reported in 1952.1 Only
sporadic cases of ZIKV in humans were reported in Africa and
Asia before 2007, when signiﬁcant outbreaks were registered
outside these regions – on the islands of Micronesia, French
Polynesia and New Caledonia in the Paciﬁc Ocean.2 In Brazil,
the ﬁrst autochthonous ZIKV transmission was reported in
the northeastern region in May 2015.3 It is believed that ZIKV
was introduced in Brazil by asymptomatic travelers during
the 2014 World Cup or by the World Sprint Championship
canoe race.4,5 ZIKV has similar characteristics to Dengue virus
in relation to epidemiology and the transmission cycle in
urban environments.6 Therefore, we should expect that, due
to the large distribution of the arthropod vectors (Aedes aegypti
mosquitoes), the number of outbreaks and symptomatic cases
might propagate.
In Brazil, there are 17 ofﬁcially conﬁrmed ZIKV cases in
three states: Bahia, Rio Grande do Norte and São Paulo.7
However, with the spread of ZIKV in the country, the World
Health Organization (WHO) has already reported ZIKV in 14
Brazilian states including Alagoas, Bahia, Ceará, Maranhão,
Mato Grosso, Pará, Paraíba, Paraná, Pernambuco, Piauí, Rio
de Janeiro, Rio Grande do Norte, Roraima, and São Paulo.8
Currently, Brazil is evidencing a high number of cases of
microcephaly, mainly in the northeastern part of the country,
which was believed to be linked to ZIKV infection acquired
during pregnancy. However, this cannot be conﬁrmed due
to insufﬁcient scientiﬁc support as ZIKV RNA was found in
the amniotic ﬂuid of only two cases. If this condition is
found to be related to ZIKV, it will represent a novel clini-
cal manifestation of this emerging virus. Other neurological
disorders correlated to ZIKV manifestations include: Guillain-
Barré syndrome, encephalitis, myelitis, meningoencephalitis,
and optical neuritis.9
Since ZIKV is an blood-borne virus transmitted by arthro-
pods, it represents potential risk for transfusion safety.
Although the signiﬁcance of ZIKV to the blood transfusion
process and use of blood derivatives is currently unknown,
there is a risk that ZIKV could also be transmitted by trans-
fusions. A high number of asymptomatic blood donors was
observed during the French Polynesia outbreak. However, sev-
eral questions remain unclear related to the possible impact transfusion  safety
of ZIKV in blood transfusion and transfusion medicine in
general:
1. The potential of ZIKV to cause asymptomatic cases must be elu-
cidated.  Asymptomatic cases of ZIKV among blood donors
(up to 74%) have been reported.10 Therefore, the poten-
tial of transmission by transfusion exits. To calculate the
transfusion-transmission model, it is important to esti-
mate the incidence of infection and the average duration
of viremia.11 However, even at a global level, there is no
information about the incidence of infection in the general
population and the events related to the viremic phase of
ZIKV infection.
2. Viral load of ZIKV infection. Viral load during ZIKV infection
has previously been measured in blood samples of asymp-
tomatic blood donors (3.40–6.91 log copies/mL).12 Addition-
ally, viral load has been detected in urine 10 to 20 days after
the onset of the disease (0.7–220 × 106 copies/mL).13 There-
fore, transfusion-transmitted ZIKV infection is possible.
However, more  detailed studies concerning the quantity
and viremia period in asymptomatic individuals are essen-
tial.
3. Effectiveness of transmission via blood transfusion. Until now,
the effectiveness of the transmission of ZIKV via transfu-
sion of blood is unknown. As other ﬂaviviruses, such as
Dengue virus 1–4 and West Nile virus,11 can be transmit-
ted by blood transfusion and cause clinical symptoms in
blood recipients,14 the transmission of ZIKV by transfu-
sions seems possible.
4. Inactivation of ZIKV in blood. It seems that ZIKV is sensitive
to blood pathogen inactivation procedures. The application
of amotosalen and ultraviolet A illumination reduces viral
titers in plasma and ZIKV does not productively infect cell
cultures. In addition, by the second passage in cell cultures,
ZIKV RNA becomes undetectable.15 Therefore, the proce-
dures of pathogen inactivation in blood seem to be effective
to inactivate ZIKV and prevent transfusion-transmitted
infection.5. Molecular diagnosis of ZIKV during screening for blood donation.
In Brazil, no serological or molecular tests for ZIKV have
been approved by the Ministry of Health. The diagnosis is
currently made by isolation of the virus in cell cultures
and molecular detection by in-house polymerase chain
oter. 
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reaction systems in Reference Laboratories. The immedi-
ate implantation of molecular tests to screen blood donors
at this moment seems unfeasible. This is not only due
to the high cost of molecular testing but also to the fact
that the pathogenesis of ZIKV infection is not fully under-
stood. Moreover, ZIKV infection is seasonal as more  cases
are reported during the peak proliferation period of the
transmitting arthropod vectors, therefore the implemen-
tation of blood donor screening for ZIKV should follow the
seasonality of infection.
. Conduct and deferral of blood donors from donation. Brazilian
blood banks should intensify the pre-donation screening
to minimize the risk of the transmission of ZIKV by trans-
fusions. It is important to pay attention to possible disease
risk factors (signs and symptoms of an arboviral disease,
travel to endemic areas, etc.) in blood donor candidates. We
also recommend that blood banks offer educational pro-
grams about ZIKV infection to alert about the potential risk
of the transmission of this emerging virus.
onclusion
IKV is an emerging virus in Brazil. In the majority of cases,
he infection is asymptomatic however mild to severe clini-
al symptoms have also been described. The efﬁciency of the
ransmission of ZIKV by transfusions is still unknown and
dditional studies are needed to better evaluate the proportion
f asymptomatic blood donors infected by ZIKV, the duration
f viremia before clinical signs of acute arboviral infection
ppear, and the clinical outcomes of ZIKV infection. Until now,
he only preventive measures to control ZIKV infection are
tringent vector control and individual precautions in respect
o mosquito bites.
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